State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives
Pilar García-Alfonso
1
,
Manuel Valladares-Ayerbes
2
,
Andrés J. Muñoz Martín
1
,
Rocío Morales Herrero
2
,
Elisa Galvez Muñoz
3
,
Gerard Prat-Llorens
4
2
Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBIS)
|
3
Pivotal SLU
4
AMGEN S.A
Publication type: Journal Article
Publication date: 2025-03-12
scimago Q1
wos Q2
SJR: 1.150
CiteScore: 7.6
Impact factor: 4.0
ISSN: 14712598, 17447682
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1
Total citations:
1
Citations from 0:
0
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
García-Alfonso P. et al. State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives // Expert Opinion on Biological Therapy. 2025. Vol. 25. No. 4. pp. 413-423.
GOST all authors (up to 50)
Copy
García-Alfonso P., Valladares-Ayerbes M., Muñoz Martín A. J., Morales Herrero R., Galvez Muñoz E., Prat-Llorens G. State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives // Expert Opinion on Biological Therapy. 2025. Vol. 25. No. 4. pp. 413-423.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1080/14712598.2025.2477192
UR - https://www.tandfonline.com/doi/full/10.1080/14712598.2025.2477192
TI - State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives
T2 - Expert Opinion on Biological Therapy
AU - García-Alfonso, Pilar
AU - Valladares-Ayerbes, Manuel
AU - Muñoz Martín, Andrés J.
AU - Morales Herrero, Rocío
AU - Galvez Muñoz, Elisa
AU - Prat-Llorens, Gerard
PY - 2025
DA - 2025/03/12
PB - Taylor & Francis
SP - 413-423
IS - 4
VL - 25
SN - 1471-2598
SN - 1744-7682
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2025_García-Alfonso,
author = {Pilar García-Alfonso and Manuel Valladares-Ayerbes and Andrés J. Muñoz Martín and Rocío Morales Herrero and Elisa Galvez Muñoz and Gerard Prat-Llorens},
title = {State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives},
journal = {Expert Opinion on Biological Therapy},
year = {2025},
volume = {25},
publisher = {Taylor & Francis},
month = {mar},
url = {https://www.tandfonline.com/doi/full/10.1080/14712598.2025.2477192},
number = {4},
pages = {413--423},
doi = {10.1080/14712598.2025.2477192}
}
Cite this
MLA
Copy
García-Alfonso, Pilar, et al. “State of the art of the molecular hyperselection to guide treatment with anti-egfr antibodies in RAS WT mCRC: implications for clinical practice and future perspectives.” Expert Opinion on Biological Therapy, vol. 25, no. 4, Mar. 2025, pp. 413-423. https://www.tandfonline.com/doi/full/10.1080/14712598.2025.2477192.